Retinal diseases caused by cone photoreceptor cell death are devastating as the patients are experiencing loss of accurate and color vision. Understanding the mechanisms of cone cell death and the identification of key players therein could provide new treatment options. We studied the neuroprotective effects of a histone deacetylase inhibitor, Trichostatin A (TSA), in a mouse model of inherited, primary cone degeneration (cpfl1). We show that HDAC inhibition protects cones in vitro, in retinal explant cultures. More importantly, in vivo a single TSA injection increased cone survival for up to 10 days post-injection. In addition, the abnormal, incomplete cone migration pattern in the cpfl1 retina was significantly improved by HDAC inhibition. These findings suggest a crucial role for HDAC activity in primary cone degeneration and highlight a new avenue for future therapy developments for cone dystrophies and diseases associated with impaired cone migration.
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Introduction
Cone photoreceptors in the human retina are responsible for sharp high resolution vision and color discrimination. Hereditary cone degenerations, such as in Stargardt and Best disease, achromatopsia, and cone dystrophies are caused by mutations in single genes, and lead to severe visual impairment, reduced visual acuity, and loss of color vision. Cone dystrophies are characterized by a high genetic heterogeneity with a large variety of mutations in at least 27 genes (RetNet: https://sph.uth.edu/retnet). In addition, genetic causes have also been proposed for complex diseases affecting cones, such as in age-related-macular degeneration (AMD) or diabetic retinopathy (DR). Irrespective of the genetic causes, a common outcome of retinal diseases is neuronal cell death, giving a strong rationale for targeted neuroprotective approaches that may prevent or delay cell death execution 1 .
The cone photoreceptor function loss-1 (cpfl1) mutant mouse is an animal model for autosomal recessive achromatopsia or progressive cone dystrophy 2 . The cpfl1 mouse model is unique in the sense that it is characterized by an early onset of cone loss at post-natal day 14
(PN14) and a fast progression with the peak of cell death at PN24 3 . We have previously shown that photoreceptor cell death in the cpfl1 mouse, as well as in nine other animal models for inherited retinal degeneration, follows a non-apoptotic mechanism, characterized by accumulation of cGMP, increased activities of cGMP-dependent protein kinase (PKG), histone deacetylase (HDAC), poly-ADP-ribose-polymerase (PARP), and calpain proteases, as well as accumulation of poly-ADP-ribose (PAR) 4 . In addition, the cpfl1 cone degeneration is also associated with prominent defects in cone migration 3 .
A common non-apoptotic cell death mechanism in different retinal degeneration models provides a rationale for the identification of therapeutic targets that would prove beneficial for a broader population of patients suffering from a variety of different genetic causes 4, 5 . While, 4 4 numerous attempts to restrain the execution of rod photoreceptor cell death were described 5, 6, 7, 8, 9 to date, an effective clinical treatment for primary cone photoreceptor degeneration has not been reported. Since humans use mostly cones for their vision, a development of treatment protocols to preserve cones is of highest priority in clinical ophthalmology.
The interplay between histone acetylation and deacetylation, performed by histone acetyltransferases (HATs) and histone deacetylases (HDACs) respectively, determines the transcription state of genes in general 10 , and this is also true for photoreceptor-specific genes 11, 12 . Aberrant activity of histone deacetylases is associated with a number of diseases with very different etiology, ranging from cancer to neurodegenerative diseases 13 . Consequently, in current medicine, HDAC inhibition is discussed as one of the most promising novel therapeutic approaches for various diseases 14 .
In the present study, we tested the hypothesis that hereditary cone degeneration can be prevented or delayed by pharmacologically inhibiting HDAC. We assessed cone photoreceptor survival after HDAC inhibition with Trichostatin A (TSA) in vitro on retinal explant cultures obtained from cpfl1 animals, as well as in vivo after intravitreal injection. We show that a single TSA injection in vivo achieved protection of cone photoreceptors, up to ten days post-injection.
In addition, we observed a significant improvement of impaired cone migration, present in degenerating cpfl1 retina. Our study shows for the first time the possibility to use pharmacological HDAC inhibition for massive cone protection in an inherited cone dystrophy.
These results may be highly relevant for the future development of therapies aimed at cone photoreceptor preservation.
Results

HDAC activity is increased in cpfl1 photoreceptors
We have previously shown that the cpfl1 cone photoreceptor degeneration follows a nonapoptotic cell death mechanism characterized by increased HDAC activity at the peak of 5 5 degeneration at PN24 4 . In this study, we evaluated HDAC activity also at the onset of cone degeneration (PN14). As soon as cpfl1 cone degeneration was detectable by TUNEL staining, we found significantly more HDAC activity positive photoreceptors in mutant retinas compared to wild-type (wt) (see Supplementary Fig. S1 ). The percentage of cells positive for HDAC activity in the photoreceptor layer corresponded to the percentage of dying photoreceptors at PN14, suggesting that increased HDAC activity was related to cone degeneration.
HDAC inhibition with TSA rescues degenerating cones in vitro
To test whether HDAC inhibition could promote cone photoreceptor survival, we used cpfl1 long-term organotypic retinal explant cultures as in vitro system. Both cpfl1 and wt retinas were explanted at the onset of cpfl1 degeneration (PN14) and cultured for 2 days without any treatment. Explanted retinas were then exposed to 10 nM TSA treatment every second day, until PN24. TSA had no effect on cone photoreceptors in wt cultures, as assessed by the percentage of cones in the outer nuclear layer (ONL), identified by labeling with an antibody for glycogen phosphorylase (Glyphos) (TSA: 4.62% ± 1.98 SEM, n=3; untreated: 4.2% ± 0.55, n=4; Figure 1 ). In the cpfl1 retina, however, 10 nM TSA significantly increased the percentage of surviving cones from 2.21% ± 0.32 SEM (n=7) to 4.6% ± 0.47 (n=6, p= 0.0013; Figure 1 ), which corresponded to an increase from 47.6% to 99.5% cones, when compared to the wt situation.
Hence, HDAC inhibition appeared to afford a full protection of cpfl1 cones.
Intravitreal TSA injection protects degenerating cones in vivo
The promising in vitro results prompted us to also engage in a study to evaluate the protective effects of HDAC inhibition in vivo. To optimize the in vivo treatment scheme, we first tried to predict the potential half-life of the drug inside the eye. Model calculations suggested that intravitreal clearance of TSA in the rabbit eye is 0.478 ml/h, and the half-life is in the range of 
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Since the protective effect of TSA might have been due to a delay of cone maturation in cpfl1
animals it was important to characterize the status of cone differentiation. To this end, we looked for the expression and localization of M-and S-opsins as well as cone-specific transducin (GNAT2), previously reported to be abnormally distributed in degenerating cones 15 .
Although M-opsin is present in cpfl1 cone outer segments, several cones showed opsin mislocalization in the cell body (Fig. 3g , arrows) and photoreceptor end feet (Fig. 3g, arrowheads). A similar but more pronounced mislocalization was observed for GNAT2 ( 
HDAC inhibition significantly improves impaired cone migration
We previously reported that the cpfl1 retina is characterized by impaired migration of developing cones 3 . Glyphos staining of cones in degenerating cpfl1 retina confirmed such aberrant cone positioning, both in vitro and in vivo (Fig. 4) . Importantly, we observed an improved migration of cones after both in vitro and in vivo TSA treatments of retinas (Fig. 4) . To evaluate the extent of the cone migration improvement, we measured the distance of the center of individual cone nuclei from the outer plexiform layer (Fig. 4 We have previously found high cGMP accumulation and activity of cGMP-dependent PKG to be associated with cpfl1 cone death as well as with cone mislocalization 3 . To investigate whether HDAC inhibition at early PN14 had an effect on cGMP accumulation and PKG activity after ten days of treatment, we looked for cGMP accumulation and the phosphorylation status of a well-known PKG substrate, vasodilator-stimulated-protein (pVASP), with and without TSA treatment. Untreated cpfl1 retinas showed cGMP accumulation in cone segments as well as in cone cell bodies (as evidenced by Glyphos co-labeling). cGMP accumulation could still be detected in cone segments after TSA treatment but was not observed in cone cell bodies (see Supplementary Fig. S3a ). Likewise, some cones, visualized by Glyphos staining, were also positive for pVASP in both TSA treated and untreated cpfl1 retinas, with no evident differences between the two (Fig. S3b ). HDAC inhibition has been demonstrated to induce cell death in tumor cells derived from various cancers 16 , while in neurodegenerative diseases, the same treatments may prolong cell survival in postmitotic neurons 17 . In the retina, HDAC inhibitors have been discussed as a potential therapeutic strategy for ischemic retinal degeneration, where HDAC inhibition with different inhibitors afforded structural and functional neuroprotection in a model of ischemic retinal injury 18 . Furthermore, HDAC inhibition was shown to slow rod photoreceptor degeneration in an animal model for Retinitis Pigmentosa 19 . In cpfl1 retina, a previous study found an upregulation of STAT3 signaling which was suggested as an endogenous neuroprotective response 20 . Interestingly, STAT3 activation may be controlled by HDAC activity 21 . We show here for the first time that HDAC inhibition almost fully protects cones in a hereditary retinal dystrophy. Besides its implication for future treatment of rare forms of retinal degeneration, the results presented here may also extend to common diseases of the retina, including diabetic retinopathy and age related macular degeneration, where cone degeneration is the cause of legal blindness. In addition, even though gene therapy is currently the only approach to significantly improve vision in patients suffering from hereditary retinal degenerations, photoreceptor cell death in treated patients is not prevented 22 . This implies a need for a combined therapy to repair both the genetic defect and to preserve neuronal viability.
In cpfl1 mice, a previous study showed that interference with thyroid hormone signalling preserved cones to some extent 23 . Significantly, this protective effect may have been dependent on the inhibition of thyroid hormone T3 binding to HDAC, which can also be 1 0 1 0 disrupted by TSA 24 . However, TSA affects HDAC more directly than anti-thyroid treatment, which may explain the fact that we see almost full cone protection, for the first time in a model for hereditary cone degeneration. Importantly, TSA did not need repeated administration and a single in vivo injection was sufficient to halt degeneration with a long lasting effect, as the protection was present even ten days post-injection. This is unexpected, as our calculations on TSA clearance suggested that the drug was below threshold concentration, after less than 2 hours and point to an imprinting mechanism, beyond the transient presence of TSA. This is in line with previous studies which found that TSA leads to robust protein acetylation after 3 hours 11 or to transcriptional changes after only 5 minutes 25 , supporting the possibility of epigenetic mechanisms. Importantly, TSA clearance estimation suggested that cone degeneration was halted with a single, short-time intraocular exposure. This observation could be relevant in light of minimizing potential toxic effects observed in some cases of long-term, systemic HDAC inhibition 26, 27 . Cone photoreceptor development is characterized by a migration within the ONL, from the outer limiting membrane inwards to the OPL and then outwards until they reach their final position, just below the outer limiting membrane, from PN12 onwards 28 . It has previously been reported that cone degeneration in mouse models is characterized not only by cone loss, but also by improper developmental cone migration 3, 29 . In fact, delayed cone migration was also reported in mouse models with rod degeneration as an indirect consequence of rod cell death 28 . Migration of cone photoreceptors is also present in human retinal development, where cones are migrating laterally towards the foveal pit 30 . Cone misplacement was also associated with human retinal diseases of different etiology as improper cone migration can lead to foveal hypoplasia 31 , an abnormal foveal structure. Abnormal foveal structure is observed in patients suffering from albinism 32 , idiopathic congenital nystagmus 31 , and also from achromatopsia 33 .
In addition, cone misplacement was also reported in patients suffering from age-related macular degeneration 34 . We found that TSA treatment not only prevented cone degeneration but also significantly improved aberrant cone migration in degenerating cpfl1 retina. There are numerous While we found cone protection after late postnatal (PN14) HDAC inhibition, HDAC activity is also crucial for mouse photoreceptor development as HDAC inhibition at early postnatal retinal development (PN2) leads to a complete loss of developing rod photoreceptors 43 . In mouse retina cone photoreceptors are born prenatally 44 , even though the full maturation and commitment towards blue cones (S cones) or red/green cones (M cones) takes place during the second postnatal week 45 . Since we performed HDAC inhibition at roughly the same time, we assessed the expression and localization of S-and M-opsin to address whether the observed increase in cone survival following HDAC inhibition may be due to cone development and maturation delays. In addition, we checked for the cone specific transducin (GNAT2) as a member of the cone phototransduction cascade 46 . The observed correct localization of cone opsins and transducin suggest that late postnatal HDAC inhibition did not delay cone development and maturation. However, we cannot exclude the possibility that the rapid degeneration of cpfl1 cones was in part caused also by developmental effects. In this case TSA treatment, at a critical period, may have enabled normal development as the observed effects hereditary cone dystrophies but also for other complex and more common cone diseases, such as diabetic retinopathy and age-related macular degeneration, associated with cone degeneration and improper cone migration.
Materials and Methods
Animals
Cpfl1 and congenic C57BL/6 wild-type (wt) animals were housed under standard white cyclic lighting, had free access to food and water, and were used irrespective of gender. Alexa Fluor 488-or 566-conjugated were used as secondary antibodies (Molecular Probes, Inc.
Eugene, USA). Negative controls were carried out by omitting the primary antibody. Specificity of cone labeling with glycogen phosphorylase (Glyphos) was shown by co-labelling with Glyphos and peanut-agglutinin (see Supplementary Fig. S5 ), a well-established marker for cones 49 .
HDAC in situ activity assay in assay buffer (50 mM Tris/HCl, pH 8.0; 137 mM NaCl; 2.7 mM KCl; 1 mM MgCl2) 7 . Negative controls consisted of omitting the substrate (Supplementary Figure 1e) .
Retinal explant cultures
Organotypic retinal cultures from cpfl1 (n=7) and wt (n=4) animals that included the retinal pigment epithelium (RPE) were prepared under sterile conditions. Briefly, PN14 animals were sacrificed, the eyes enucleated and pretreated with 12% proteinase K (ICN Biomedicals Inc., OH, USA) for 15 minutes at 37°C in R16 serum free culture medium (Invitrogen Life
Technologies, Paisley, UK). Proteinase K was blocked by addition of 10% fetal bovine serum, followed by rinsing in serum-free medium. Following this, cornea, lens, sclera and choroid were removed carefully, with only the RPE remaining attached to the retina. The explant was then cut 1 5 1 5
into four wedges to give a clover-leaf like structure which was transferred to a culture membrane insert (Corning Life Sciences, Lowell, USA) with the RPE facing the membrane. The membrane inserts were placed into six well culture plates with R16 medium and incubated at 37°C in a humidified 5% CO 2 incubator. The culture medium was changed every 2 days during the 10 culturing days.
Retinal explants were left without treatment for 2 days (until PN16), followed by Trichostatin A treatment (≥98% (HPLC), from Streptomyces sp., Sigma-Aldrich, St-Louis, USA) in two concentrations: 10 or 100 nM. Trichostatin A (TSA) was dissolved in 0.2% dimethyl sulfoxide (DMSO; Sigma) and diluted in R16 culture medium. For controls, the same amount of DMSO was diluted in culture medium. Culturing was stopped at PN24 by 2 h fixation in 4% PFA, cryoprotected with 30% sucrose and then embedded in tissue freezing medium (Leica Microsystems Nussloch GmbH, Nussloch, Germany).
In vivo injections
Animals were anesthetized with an intraperitoneal injection of Ketamine (100ng/kg) Xylazin (5mg/kg) (Bela-Pharm, Vechta, Germany/Bayer Vital, Leverkusen, Germany), eye lids were anesthetized locally with Novesin (Omnivision, Puchheim, Germany) and animals were kept warm during injections. Single intravitreal injections were performed at PN14 on one eye while the other eye was sham injected with 0.0001% DMSO as contralateral control. TSA (1 and 10 nM) was diluted in 0.9% NaCl solution, which was also used for sham treatment. Injections were performed with 0.5 µl of 10 nM and 100 nm TSA in order to have a final concentration of 1 nM and 10 nM, respectively, assuming the free intraocular volume of mouse eye to be 5µl
(http://prometheus.med.utah.edu/~marclab/protocols.html). Eleven cpfl1 animals and eight wt from three different litters were used for intravitreal injections and were sacrificed 10 days after treatment (PN24). Eyes were immediately enucleated, fixed for 2 h in 4% PFA and prepared for directed against S-opsin (b, h, n) and transducin (GNAT2; arrows; c, i, o). However, after TSA treatment, not only were there more cones, but M-opsin, S-opsin, as well as GNAT2 were properly localized almost exclusively in outer segments (p-r). Scale bar is 20 µm. 
